Key facts
- Notable investors include Active Partners, Redrice Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Epetōme
- ·The full record, as it builds
Funding rounds
No funding rounds for Epetōme are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Epetōme
Provider of dietary supplements intended for digestive and microbiome support. The company's platform offers a once-daily capsule-in-capsule supplement containing a prebiotic component, shelf-stable storage, and targeted release technology, enabling health-conscious consumers to support gut, immune, and overall wellbeing through a structured daily regimen.
- Sector
- Healthcare
- HQ
- Leeds, United Kingdom
- Founded
- 2023
- Employees
- 10
- Website
- epetome.com/
- Ownership
- Privately Held (backing)
Epetōme doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Epetōme shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Epetōme in its N-PORT filings yet. We sweep new filings monthly.